GET DAILY SIGNALSCuris (CRIS) Drops -17.8% Over 30 Days Following Dilutive Placement
Key Takeaways
- Curis (CRIS) shares fell roughly 17.8% over the trailing 30 days, from about $0.80 in early October to approximately $0.66.
- The decline was driven primarily by a dilutive $8.5 million private placement announced on October 16, 2026, priced at $0.51 per share with accompanying warrants at $0.60.
- Over the broader quarter, the stock has fallen from around $5.15 in early August, pressured by multiple dilutive financings and ongoing cash-burn concerns.
- Curis's investment thesis centers on emavusertib, its oral IRAK4 and FLT3 inhibitor in development for primary CNS lymphoma (PCNSL) and chronic lymphocytic leukemia (CLL).
- The company reported positive updated PCNSL data in July 2026, and initial CLL combination data from 5–10 patients is expected in December 2026.
- Proceeds from the October placement are intended to fund operations through that initial CLL data readout.
Curis and Its Core Pipeline
Curis, Inc. is a clinical-stage biotechnology company centered on emavusertib (CA-4948), an orally available small-molecule inhibitor of IRAK4 and FLT3. The asset is advancing in the TakeAim Lymphoma Phase 1/2 study in combination with ibrutinib for relapsed or refractory primary CNS lymphoma, and in the TakeAim CLL Phase 2 study with zanubrutinib for chronic lymphocytic leukemia. Curis licensed the compound through its 2015 collaboration with Aurigene Discovery Technologies. Emavusertib holds Orphan Drug Designation from the FDA for PCNSL, AML, and MDS, as well as from the European Commission for PCNSL. As a pre-revenue company with one lead asset, its valuation remains tightly linked to clinical progress and capital access.
Stock Performance: The Past 30 Days and the Quarter
Over the last 30 days, CRIS moved from a closing price of $0.8034 on October 2, 2026, to roughly $0.66 in early November, a decline of about -17.8%. The drop concentrated around the mid-October financing announcement, with shares later showing a partial rebound into month-end. The quarterly view is more severe. From a close near $5.15 in early August 2026, the stock has fallen to approximately $0.66, representing a decline of roughly 87%. Successive equity raises at lower prices and persistent cash-burn concerns have weighed on the shares even as clinical programs moved forward. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The October Financing and Its Market Impact
The key driver in the recent period was the October 16, 2026 announcement of an approximately $8.5 million private placement. The company agreed to sell 16,666,680 shares or pre-funded warrants, along with common warrants, at an effective price of $0.51 per share. The common warrants carry a $0.60 exercise price, become exercisable after six months, and expire in five and a half years. Certain earlier warrants from January and August 2026 also had their exercise prices reset to $0.60. Because the placement came in below market with meaningful warrant coverage, it signaled further dilution and pressured the stock in the days after the announcement. Proceeds are earmarked for research and development plus general corporate purposes, and the company indicated they would support operations through the initial CLL data readout expected in December 2026.
Quarterly Pressures and Clinical Context
The broader quarterly decline follows a pattern of capital raises at successively lower valuations. An August 2026 financing that included warrants with a $1.75 exercise price contributed to a sharp selloff from roughly $5 in early August to about $1.60 by mid-August. The October placement at $0.51 compounded those concerns. On the positive side, Curis released updated data in July 2026 from the TakeAim Lymphoma study in PCNSL, showing a 100% overall response rate among BTKi-naïve evaluable patients and a 26% response rate among BTKi-experienced patients. The TakeAim CLL program has begun dosing patients, with the December 2026 data milestone reaffirmed. Clinical updates provided some support, yet financing risk and cash-runway questions dominated sentiment over the quarter.
Key Catalysts Ahead for Investors
The most immediate event remains the initial CLL data readout expected in December 2026 from the TakeAim CLL study of emavusertib plus zanubrutinib in 5–10 patients. Updated PCNSL data from the TakeAim Lymphoma study is anticipated in the first half of 2027 and could inform potential regulatory filings. Additional factors to monitor include the company’s cash position, any further financing activity, progress toward Nasdaq listing compliance, and overall biotech-sector sentiment. These elements carry meaningful risk and do not guarantee future results.
AI Tools in My Research Process
I frequently review algorithmic strategies alongside fundamental analysis when evaluating names like CRIS. Tickeron’s Trending AI Robots page highlights top-performing bots across thousands of tickers, allowing a focused comparison of different trading approaches and timeframes without relying on any single signal.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CRIS's RSI Oscillator ascending out of oversold territory
The RSI Indicator for CRIS moved out of oversold territory on October 28, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 40 similar instances when the indicator left oversold territory. In 36 of the 40 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on CRIS as a result. In 56 of 75 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
Following a +18.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRIS advanced for three days, in 137 of 181 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 37 of 42 cases where CRIS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRIS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
CRIS broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CRIS entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 46 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 79 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.369) is normal, around the industry mean (3.051). P/E Ratio (0.196) is within average values for comparable stocks, (-0.872). Projected Growth (PEG Ratio) (3.280) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (125.677) among similar stocks. P/S Ratio (0.301) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 95 (best 1 - 100 worst), indicating slightly worse than average price growth. CRIS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 96 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRIS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a drug company
Industry Biotechnology
Advertisement